EU to terminate vaccine agreement with Valneva

A lacking marketing approval has allowed the European Commission to terminate its Covid-19 vaccine purchasing agreement with Valneva.

Photo: David Vincent/AP/Ritzau Scanpix

On Monday, French vaccine maker Valneva is being punished by investors on the Paris stock exchange following news that the EU is intending to terminate its purchasing agreement on Covid-19 vaccines.

According to Bloomberg News, this could impact Valneva’s 2022 guidance, and expectations could be reconsidered based on negotiations with the European Commission.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs